Rab5if是NSCLC的一个潜在的治疗点
Linjuan Lu1, Lixiu Chen1, Feng Gao1
1Department of Respiratory and Critical Care Medicine, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, China.
Cancer genetics
|May 3, 2025
概括
Rab5if促进非小细胞肺癌 (NSCLC) 的生长和迁移. 向Rab5if可能为NSCLC提供一种新的治疗策略,因为抑制其表达可以在体外和体内减少瘤进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 非小细胞肺癌 (NSCLC) 仍然是全球癌症死亡的主要原因.
- 高死亡率归因于疾病进展和获得的耐药性.
- 新的治疗目标对于改善NSCLC治疗结果至关重要.
研究的目的:
- 调查Rab5if在NSCLC的发展和进展中的作用.
- 探索Rab5if作为NSCLC治疗的治疗点的潜力.
主要方法:
- 使用lentivirus构建Rab5if过度表达和淘汰NSCLC细胞系.
- 在体外细胞测试以评估增殖,迁移和线粒体功能.
- 西方斑点分析以阐明潜在的分子机制.
- 在裸体小鼠体内异种移植研究以验证体外发现.
主要成果:
- Rab5if在NSCLC组织和细胞系中mRNA和蛋白质水平升高.
- Rab5if knockdown显著抑制了NSCLC细胞的增殖,迁移和线粒体功能.
- Rab5if过度表达促进了NSCLC细胞的增殖和迁移.
- 确定了AKT-mTOR通路是调解Rab5if作用的关键机制.
- 在体内研究证实,Rab5if knockdown抑制了瘤生长,而过度表达则加速了瘤生长.
结论:
- Rab5if在NSCLC的进展中发挥着重要作用.
- Rab5if是NSCLC治疗的潜在新型治疗点.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.1K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
981
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
The Retinoblastoma Gene
4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
Small GTPases - Ras and Rho
3.8K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.8K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
